Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Bradley A. Erickson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5237-3464; OpenAlex author ID A5023172194. Sources: OpenAlex.

Their work

Papers
54 (first author 7, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
80
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 5 papers · 2015: 4 papers · 2016: 6 papers · 2017: 6 papers · 2018: 5 papers · 2019: 2 papers · 2020: 8 papers · 2021: 6 papers · 2022: none · 2023: 5 papers · 2024: 2 papers · 2025: 2 papers

Papers 50 of 54

  1. Local Disease Control in Patients With Pancreatic Cancer. First author DOI 10.1001/jamaoncol.2025.0156↗
  2. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  3. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  4. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  5. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  6. Predicting Treatment Response From Extracellular Volume Fraction for Chemoradiation Therapy of Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2022.09.084↗
  7. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  8. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Res… Co-author DOI 10.1245/s10434-022-12742-3↗
  9. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  10. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Co-author DOI 10.1007/s10555-021-09993-z↗
  11. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Co-author DOI 10.1016/j.amjsurg.2020.12.001↗
  12. Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer. First author DOI 10.1016/j.soc.2021.06.009↗
  13. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.06.038↗
  14. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  15. Magnetic Resonance Guided Radiation Therapy for Pancreatic Adenocarcinoma, Advantages, Challenges, Current Approaches, and Future Directions. Last author DOI 10.3389/fonc.2021.628155↗
  16. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? Co-author DOI 10.1007/s11605-019-04423-6↗
  17. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  18. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Last author DOI 10.1016/j.prro.2020.01.012↗
  19. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  20. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003049↗
  21. Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI bas… Co-author DOI 10.1371/journal.pone.0236570↗
  22. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  23. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  24. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  25. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  26. The role of imaging in the clinical practice of radiation oncology for pancreatic cancer. Co-author DOI 10.1007/s00261-017-1373-3↗
  27. Correlation of ADC With Pathological Treatment Response for Radiation Therapy of Pancreatic Cancer. First author DOI 10.1016/j.tranon.2018.01.018↗
  28. PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study. Co-author DOI 10.1016/j.tranon.2018.06.011↗
  29. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002957↗
  30. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Co-author DOI 10.1259/bjr.20170563↗
  31. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3319-4↗
  32. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗
  33. Recommendations for MRI-based contouring of gross tumor volume and organs at risk for radiation therapy of pancreatic cancer. Last author DOI 10.1016/j.prro.2016.10.006↗
  34. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Last author DOI 10.1016/j.prro.2017.06.013↗
  35. Considerations Regarding the Role of Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma in the Elderly. First author DOI 10.1200/jop.2017.022087↗
  36. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. Co-author DOI 10.1371/journal.pone.0178961↗
  37. Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. Co-author DOI 10.1002/jso.24316↗
  38. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? Co-author DOI 10.1002/jso.24361↗
  39. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Co-author DOI 10.1016/j.surg.2015.09.018↗
  40. Preliminary results on the feasibility of using ultrasound to monitor intrafractional motion during radiation therapy for pancreatic cancer. First author DOI 10.1118/1.4960004↗
  41. Evolution of the Management of Resectable Pancreatic Cancer. First author DOI 10.1200/jop.2016.015818↗
  42. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Co-author DOI 10.1200/jop.2016.016162↗
  43. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.06.017↗
  44. Neoadjuvant therapy for localized pancreatic cancer: support is growing? Last author DOI 10.1097/sla.0000000000000996↗
  45. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. Co-author DOI 10.1111/hpb.12448↗
  46. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. Co-author DOI 10.3978/j.issn.2078-6891.2015.053↗
  47. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s11605-014-2635-9↗
  48. Variability of target and normal structure delineation using multimodality imaging for radiation therapy of pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2014.02.035↗
  49. Radiation dose responses for chemoradiation therapy of pancreatic cancer: an analysis of compiled clinical data using biophysical models. Co-author DOI 10.1016/j.prro.2013.01.005↗
  50. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Last author DOI 10.1016/j.radonc.2014.09.010↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William Adrian Hall · 32 shared papers, 2017–2025 · strength 4.07
  2. Douglas B. Evans · 35 shared papers, 2014–2025 · strength 3.62
  3. Susan Tsai · 33 shared papers, 2014–2024 · strength 3.11
  4. Ben George · 28 shared papers, 2014–2024 · strength 2.67
  5. Kathleen K. Christians · 29 shared papers, 2014–2024 · strength 2.65
  6. Mohammed Aldakkak · 16 shared papers, 2015–2024 · strength 1.70
  7. Mandana Kamgar · 10 shared papers, 2020–2024 · strength 1.46
  8. Callisia Nathelee Clarke · 12 shared papers, 2017–2024 · strength 1.39
  9. Kulwinder S. Dua · 9 shared papers, 2016–2024 · strength 0.95
  10. Ashley N. Krepline · 11 shared papers, 2014–2021 · strength 0.88
  11. X. Allen Li · 10 shared papers, 2012–2023 · strength 0.81
  12. E.S. Paulson · 7 shared papers, 2014–2025 · strength 0.79
  13. Parag P. Tolat · 10 shared papers, 2014–2023 · strength 0.77
  14. Naveen M. Kulkarni · 5 shared papers, 2020–2023 · strength 0.60
  15. Chad A. Barnes · 6 shared papers, 2017–2020 · strength 0.53
  16. Christopher H. Crane · 4 shared papers, 2017–2021 · strength 0.49
  17. Sam Z. Thalji · 3 shared papers, 2023 · strength 0.48
  18. Joseph M. Herman · 3 shared papers, 2018–2025 · strength 0.40
  19. Eugene Jon Koay · 4 shared papers, 2017–2021 · strength 0.37
  20. Entesar Zawam Dalah · 4 shared papers, 2014–2018 · strength 0.29
  21. Michael Frederick Bassetti · 2 shared papers, 2021–2025 · strength 0.29
  22. Michael David Chuong · 2 shared papers, 2021–2025 · strength 0.29
  23. A. Tai · 4 shared papers, 2012–2018 · strength 0.28
  24. Katharine L. Aitken · 3 shared papers, 2017–2021 · strength 0.27
  25. George Noid · 2 shared papers, 2016–2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.